Domvanalimab, zimberelimab and FOLFOX shows durable survival in advanced HER2-negative GC/GEJC/EAC

Abemaciclib combined with endocrine therapy improves OS in high-risk HR+, HER2− early breast cancer

Durvalumab combined with FLOT improves survival in resectable gastric and GEJ adenocarcinoma

Enhancing breast cancer care through AI and collaboration

NSCLC brain metastases: TTFields after SRS delays intracranial progression without affecting QoL

Proton vs photon radiotherapy shows similar patient-reported quality of life in breast cancer patients

Apalutamide and salvage radiotherapy benefits luminal B subtype prostate cancer

ctDNA testing improves detection of treatable metastases compared to standard care in colorectal cancer

ADT with PORT is a good treatment option for men with unfavourable intermediate risk or favourable high risk PC

Bladder cancer updates from the first half of 2025

Improving efficacy and toxicity reporting - and treatment insights from an oncologist patient

CURB phase II trial: Tumour burden predicts survival after SBRT in NSCLC oligoprogression